A Piece in the Puzzle of Personalized Medicine

[1]  M Schwab,et al.  UDP‐Glucuronosyltransferase (UGT) Polymorphisms Affect Atorvastatin Lactonization In Vitro and In Vivo , 2010, Clinical pharmacology and therapeutics.

[2]  S. Ghosh,et al.  Utility of Adiponectin as a Biomarker Predictive of Glycemic Efficacy Is Demonstrated by Collaborative Pooling of Data From Clinical Trials Conducted by Multiple Sponsors , 2009, Clinical pharmacology and therapeutics.

[3]  K. Iwasaki,et al.  Pretransplant Pharmacodynamic Analysis of Immunosuppressive Agents Using CFSE‐Based T‐Cell Proliferation Assay , 2009, Clinical pharmacology and therapeutics.

[4]  M. Imamura,et al.  Successful hepatitis B vaccination in liver transplant recipients with donor‐specific hyporesponsiveness , 2009, Transplant international : official journal of the European Society for Organ Transplantation.

[5]  M. Daly,et al.  HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin , 2009, Nature Genetics.

[6]  S. Brouard,et al.  Can immune monitoring help to minimize immunosuppression in kidney transplantation? , 2009, Transplant international : official journal of the European Society for Organ Transplantation.

[7]  J. Chapman,et al.  Individualization of immunosuppression: concepts and rationale , 2008, Current opinion in organ transplantation.

[8]  R. Collins,et al.  SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.

[9]  G. Boden,et al.  Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. , 2007, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[10]  M. Ashiya,et al.  Non-insulin therapies for type 2 diabetes , 2007, Nature Reviews Drug Discovery.

[11]  R. Krauss,et al.  Pharmacogenomics of statin response , 2007, Current opinion in lipidology.

[12]  T. Hirano Cellular pharmacodynamics of immunosuppressive drugs for individualized medicine. , 2007, International immunopharmacology.

[13]  田中 友加 Low incidence of acute rejection after living-donor liver transplantation : immunologic analyses by mixed lymphocyte reaction using a carboxyfluorescein diacetate succinimidyl ester labeling technique , 2006 .

[14]  T. Asahara,et al.  Low Incidence of Acute Rejection after Living-Donor Liver Transplantation: Immunologic Analyses by Mixed Lymphocyte Reaction using a Carboxyfluorescein Diacetate Succinimidyl Ester Labeling Technique , 2005, Transplantation.

[15]  Richard Platt,et al.  Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. , 2004, JAMA.

[16]  T. Asahara,et al.  Multiparameter Flow Cytometric Approach for Simultaneous Evaluation of Proliferation and Cytokine‐Secreting Activity in T Cells Responding to Allo‐stimulation , 2004, Immunological investigations.

[17]  N. Lameire,et al.  Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  H. Lennernäs Clinical Pharmacokinetics of Atorvastatin , 2003, Clinical pharmacokinetics.

[19]  P. Neuvonen,et al.  Effect of itraconazole on the pharmacokinetics of atorvastatin , 1998, Clinical pharmacology and therapeutics.

[20]  H. Gudmundsdottir,et al.  Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response. , 1997, The Journal of clinical investigation.

[21]  D. Turner,et al.  Fluorescent labeling of dissociated fetal cells for tissue culture , 1992, Journal of Neuroscience Methods.

[22]  C. Orosz,et al.  SIZE OF THE DONOR‐REACTIVE CTL POOL DETERMINED BY LIMITING DILUTION ANALYSIS IN SPONGE MATRIX ALLOGRAFTS1 , 1986, Transplantation.